Anlotinib and Radiotherapy in Resectable Soft Tissue Sarcoma

Key facts

Sponsor

Ruijin Hospital

Principal Investigator

Yuhui Shen, MD

Ruijin Hospital

Intervention

Anlotinib(drug)

Enrollment

41 target

Eligibility

18 years · All sexes

Timeline

2022 – 2024

Study locations (1)

• Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Soft tissue sarcoma

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07402577
  Brief Title Mechanisms of Cancer-Related Pain and Opioid Use Among Adolescents and Young Adult Sarcoma Survivors: Pilot Feasibility Study
  Roswell Park Cancer Institute
• RECRUITINGNANCT07359911
  Effect of A Multimodal Exercise Intervention on Chemotherapy Uptake in Newly Diagnosed Pediatric and AYA Sarcoma Patients
  University of Miami
• RECRUITINGNCT07148193
  Quality of Life and Medical Care of Long-term Sarcoma Survivors in Germany (PROSa+)
  Technische Universität Dresden
• RECRUITINGPHASE1NCT07156565
  Actinium Therapy for Late-stage Aggressive Sarcomas
  Ratio Therapeutics, Inc.
• RECRUITINGNANCT07104955
  Salutare One Referral Software Impact on Multi-Disciplinary Team (MDT) Meetings Effectiveness and Safety
  Salutare Group Ltd.
• RECRUITINGPHASE1, PHASE2NCT07064018
  Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
  University of California, Irvine
• RECRUITINGNCT06962072
  Outcomes Following Limb Sparing Surgery for Soft Tissue Sarcoma
  Amsterdam UMC
• RECRUITINGPHASE2NCT06905132
  Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma
  Medical University of South Carolina

See all trials for Soft tissue sarcoma →